文献速递淋巴瘤

利用常规可及组织标本对原发纵隔大B细胞淋巴瘤进行分子分型

Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens.
PubMed 文献 · Blood · 2018-09-26

研究开发了基于福尔马林固定石蜡包埋组织的Lymph3Cx分子分型检测,含58个基因特征的概率模型在68例原发纵隔大B细胞淋巴瘤(PMBCL)与弥漫大B细胞淋巴瘤(DLBCL)中训练,并在158例独立验证队列中评估,与专家组的临床病理诊断高度一致(明确误分类率3.8%),两个独立实验室分型结果100%一致。

要点

  • Lymph3Cx基于石蜡组织基因表达区分PMBCL与DLBCL亚型,明确误分类率3.8%。
  • 两个独立实验室分型结果100%一致,显示检测可重复性。
  • 未来研究将确定Lymph3Cx用于常规诊断和治疗决策的效用。

核心结论

  • Lymph3Cx分子分型与专家组临床病理诊断高度一致,明确误分类率为3.8%,两个独立实验室分型结果100%一致。
  • 未来研究将确定Lymph3Cx用于常规诊断和治疗决策的效用。

研究设计与样本

  • 基于福尔马林固定石蜡包埋组织的基因表达测量,开发含58个基因特征、考虑分类误差的概率模型,在68例PMBCL和DLBCL病例中训练,并在158例独立验证队列中评估性能。

主要发现

  • Lymph3Cx分子分型与专家组临床病理诊断高度一致,明确误分类率为3.8%。
  • 两个独立实验室的分型结果100%一致。

关键数值与推荐

  • Lymph3Cx分子分型与专家组临床病理诊断的明确误分类率为3.8%。
  • 两个独立实验室分型结果100%一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 未来研究将确定Lymph3Cx用于常规诊断和治疗决策的效用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Primary mediastinal large B-cell lymphoma (PMBCL) is recognized as a distinct entity in the World Health Organization classification. Currently, the diagnosis relies on consensus of histopathology, clinical variables, and presentation, giving rise to diagnostic inaccuracy in routine practice. Previous studies have demonstrated that PMBCL can be distinguished from subtypes of diffuse large B-cell lymphoma (DLBCL) based on gene expression signatures. However, requirement of fresh-frozen biopsy material has precluded the transfer of gene expression-based assays to the clinic. Here, we developed a robust and accurate molecular classification assay (Lymph3Cx) for the distinction of PMBCL from DLBCL subtypes based on gene expression measurements in formalin-fixed, paraffin-embedded tissue. A probabilistic model accounting for classification error, comprising 58 gene features, was trained on 68 cases of PMBCL and DLBCL. Performance of the model was subsequently evaluated in an independent validation cohort of 158 cases and showed high agreement of the Lymph3Cx molecular classification with the clinicopathological diagnosis of an expert panel (frank misclassification rate, 3.8%). Furthermore, we demonstrate reproducibility of the assay with 100% concordance of subtype assignments at 2 independent laboratories. Future studies will determine Lymph3Cx's utility for routine diagnostic purposes and therapeutic decision making.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mottok A, Wright G, Rosenwald A, et al. Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood. 2018. PMID: 30257882. doi:10.1182/blood-2018-05-851154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。